0.7599
Tempest Therapeutics Inc stock is traded at $0.7599, with a volume of 631.79K.
It is up +6.34% in the last 24 hours and down -6.12% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$0.7146
Open:
$0.7045
24h Volume:
631.79K
Relative Volume:
0.73
Market Cap:
$31.19M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-0.4967
EPS:
-1.53
Net Cash Flow:
$-28.18M
1W Performance:
-5.15%
1M Performance:
-6.12%
6M Performance:
-43.29%
1Y Performance:
-85.07%
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TPST
Tempest Therapeutics Inc
|
0.7599 | 31.19M | 0 | -31.11M | -28.18M | -1.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World
What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World
Scotiabank Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World
Scotiabank Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $7.00 - Armenian Reporter
HC Wainwright Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World
Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges - TipRanks
H.C. Wainwright cuts Tempest Therapeutics stock target to $16 By Investing.com - Investing.com UK
Tempest Therapeutics Inc. (TPST) reports earnings - Quartz
Why Super Micro Computer Stock Was Sliding This Week - The Globe and Mail
Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire
Tempest's Cancer Drug Shows 6-Month Survival Gain, Lands Major Roche Partnership - Stock Titan
Tempest Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Tempest Announces Amezalpat Poster Presentation at the 2025 - GlobeNewswire
Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 - Stock Titan
Tempest Therapeutics advances Phase 2 trial for cancer prevention By Investing.com - Investing.com Australia
FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire
Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice - Marketscreener.com
Tempest Therapeutics advances Phase 2 trial for cancer prevention - Investing.com India
Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition - Marketscreener.com
FDA Green Light: Tempest's Revolutionary FAP Drug Advances to Phase 2 with NCI Backing - StockTitan
Tempest Therapeutics (TPST) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga
Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World
Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Decrease in Short Interest - Defense World
TPST stock rated a Sector outperform by Scotiabank - Knox Daily
Tempest gets fast track designation from FDA for amezalpat - MSN
A closer look at Tempest Therapeutics Inc (TPST)’s stock price trends - US Post News
Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Amezalpat (TPST-1120) - Marketscreener.com
Tempest Therapeutics Inc (TPST) Shares Rise Despite Market Challenges - The News Heater
Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer - Marketscreener.com
Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat - Marketscreener.com
Tempest Granted Fast Track Designation from the U.S. Food - GlobeNewswire
Tempest's Liver Cancer Breakthrough: FDA Fast-Tracks Drug Showing 6-Month Survival Gain - Stock Titan
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Therapeutics Awards Strategic Compensation Package: Inside the 4-Year Vesting Deal - StockTitan
Analyzing Ratios: Tempest Therapeutics Inc (TPST)’s Financial Story Unveiled - The Dwinnex
A stock that deserves closer examination: Tempest Therapeutics Inc (TPST) - US Post News
Tempest Therapeutics Inc (NASDAQ: TPST) – An Analysis Is What You Need - Stocks Register
Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC - Defense World
Tempest Receives Orphan Drug Designation from the U.S. Food - GlobeNewswire
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewswire Inc.
Before You Sell Tempest Therapeutics Inc (NASDAQ: TPST) Shares, Here’sWhat You Need To Know. - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges - Investing.com Canada
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges By Investing.com - Investing.com South Africa
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Tempest Therapeutics amends rights agreement By Investing.com - Investing.com Australia
Tempest Therapeutics amends rights agreement - Investing.com India
Tempest Therapeutics Awards Key Employee Stock Options in Strategic Compensation Move | TPST Stock News - StockTitan
Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):